Engineered albumin fusion allows protein drug to last longer and cross nasal barriers
Researchers from the University of Oslo and international collaborators published a study in Nature Communications on an engineered albumin fusion that extends the life of therapeutic proteins and enables non-invasive delivery through mucosal surfaces.
Fusion protein extends circulation time
The team genetically fused human erythropoietin to an engineered form of human albumin. This modified molecule remained biologically active and showed improved persistence in the bloodstream compared to standard proteins. The approach addresses the limitation that protein-based medicines are often rapidly cleared from circulation.
Non-invasive delivery tested in mice
The engineered EPO-albumin fusion protein was transported across mucosal barriers following administration through the nose. Researchers used humanized mice to demonstrate that this method works without the need for needles. This development could reduce the burden of frequent injections for patients requiring long-term treatment.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.